Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.
The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, ...
Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback